James William Smithy

16PUBLICATIONS
90CO-AUTHORS
Tumour immunologyMedical molecular engineering of nucleic acids and proteinsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Aug 13, 2026
Phase II trial of First-Line Axitinib Plus Nivolumab in Patients with Advanced Mucosal Melanoma.

|Jul 13, 2026
An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.

|Jun 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

|May 13, 2026
T-Cell Clonal Expansion in Peripheral Blood Following Interventional Radiology Procedures for Metastatic Liver Cancer.

|Apr 13, 2026
Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison.

David M Miller, James W Smithy, Jennell Palaia

|Nov 28, 2025
International real-world study of combination immunotherapy sequences in metastatic melanoma.

Mora Guardamagna, Sarah E Lochrin, James William Smithy

Pageof 3

Frequent Collaborators

6 joint publications

Michael Postow

6 joint publications

Alexander Noor Shoushtari

3 joint publications

Allison Betof Warner

3 joint publications

Ryan J Sullivan